Rep. Kevin Hern (R-Okla.) has filed a Periodic Transaction Report disclosing the sale of Biogen Inc. (BIIB) common stock, according to records submitted to the U.S. House of Representatives under the STOCK Act. The transaction, dated August 18, 2026, was made personally by Hern and held through his Kevin Hern Traditional IRA. The disclosed value of the sale falls between $1,001 and $15,000, the lowest reporting bracket used on these forms.
Whoisbuyingnow.com classifies this filing as a congress sale, part of our ongoing effort to track buy and sell activity disclosed by lawmakers across brokerage accounts, retirement vehicles, and trusts. The STOCK Act requires members of Congress and certain staff to report transactions like this one within 45 days, a transparency measure designed to let the public see potential overlap between lawmakers’ personal finances and their legislative work. Filing a report is a legal obligation, not an indication of wrongdoing.
A Notable Overlap in Timing
What makes this filing worth a closer look is its proximity to another sale of the same stock. Company insider Minor Lloyd sold BIIB shares valued at $119,169 on August 4, 2026, just two weeks before Hern’s disclosed transaction date. Both sales occurred within the same 30-day window, a pattern that our tracking flags for readers even though the two parties are not shown to be connected and no shared intent is implied by the public record. Insider sales and congressional trades are reported through separate systems, but when they cluster around the same ticker and timeframe, it becomes a data point worth surfacing rather than ignoring.
There is no indication in the filing of why Hern’s IRA sold the position, and IRA-held transactions in particular often reflect decisions made by outside portfolio managers or automated rebalancing rather than a lawmaker’s direct market view. The amount involved here is also modest relative to some other disclosures tracked on this site, sitting in the smallest reporting bracket the House uses.
Readers interested in how institutional investors are positioning around similar biotech and life-sciences names may want to review our coverage of Sofinnova Investments, Inc.: 13F Portfolio Moves, Tracked Quarterly, which tracks quarterly 13F filings from a fund specializing in that sector.
Whoisbuyingnow.com will continue monitoring subsequent filings tied to Hern’s accounts and to BIIB more broadly, including any further insider or congressional activity disclosed in the coming weeks.